Skip to Main Content

Paper Details

A phase I study of talazoparib (BMN 673) combined with carboplatin and paclitaxel in patients with advanced solid tumors (NCI9782).
Cancer Med
8
2022
BMN 673, NCI9782, PARP, Patients, Talazoparib, advanced solid tumors, carboplatin, myelosuppression, paclitaxel, patients, platinum, poly(ADP-ribose), poly(ADP-ribose) polymerase, talazoparib
Author NameAffiliation
Ruth M O'ReganUniversity of Rochester
Jyoti MalhotraRutgers Cancer Institute of New Jersey
  • 1 - 2

Datasets

Release 1.2